GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
N Alfaris, S Waldrop, V Johnson, B Boaventura… - …, 2024 - thelancet.com
Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an
increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) …
increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) …
Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use
primarily due to their weight-reduction effects, although a regulatory review was undertaken …
primarily due to their weight-reduction effects, although a regulatory review was undertaken …
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Following the publication of results from multiple landmark cardiovascular outcome trials of
antihyperglycemic medications over the past 8 years, there has been a major shift in the …
antihyperglycemic medications over the past 8 years, there has been a major shift in the …
[HTML][HTML] Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance …
A Guirguis, S Chiappini, R Vickers-Smith… - European …, 2024 - Elsevier
Introduction The study addresses concerns about potential psychiatric side effects of
Glucagon-like peptide-1 receptor agonists (GLP-1 RA). Aim The aim of this work was to …
Glucagon-like peptide-1 receptor agonists (GLP-1 RA). Aim The aim of this work was to …
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database
R Ruggiero, A Mascolo, A Spezzaferri, C Carpentieri… - Pharmaceuticals, 2024 - mdpi.com
Background: A potential risk of suicide associated with liraglutide or semaglutide treatments
has recently emerged. Therefore, we decided to investigate the reporting probability of …
has recently emerged. Therefore, we decided to investigate the reporting probability of …
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in US Older Adults With Type 2 Diabetes: A Target Trial Emulation Study
Background: A major concern has recently emerged about a potential link between
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and increased risk for suicidal …
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and increased risk for suicidal …
The association between ketamine and esketamine and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
RS McIntyre, RB Mansur, JD Rosenblat… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Replicated evidence indicates that ketamine and esketamine reduces
measures of suicidality in persons with treatment resistant depression (TRD). It remains …
measures of suicidality in persons with treatment resistant depression (TRD). It remains …
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system …
ATH Kwan, JD Rosenblat, RB Mansur… - Journal of Affective …, 2024 - Elsevier
Introduction Ketamine and esketamine have been proven to be effective in treating adults
with treatment resistant depression (TRD). Preliminary evidence indicates that, when …
with treatment resistant depression (TRD). Preliminary evidence indicates that, when …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas
RS McIntyre - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Within the last year, the European Medicines Agency (EMA), Food and Drug Administration
(FDA) and the Medicines and Healthcare Products Regulatory Agency in the United …
(FDA) and the Medicines and Healthcare Products Regulatory Agency in the United …
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA …
J Zhou, Y Zheng, B Xu, S Long, L Zhu, Y Liu, C Li… - BMC medicine, 2024 - Springer
Background Establishing whether there is a potential relationship between glucagon-like
peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is …
peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is …